We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Research Platform Assesses Brain Cancer Mutations during Surgery

By LabMedica International staff writers
Posted on 04 Jun 2024
Print article
Image: Brain cancer mutations identified during surgery (Photo courtesy of Mayo Clinic)
Image: Brain cancer mutations identified during surgery (Photo courtesy of Mayo Clinic)

Brain cancer, particularly a type known as glioma, is notoriously difficult to treat and generally has a poor five-year survival rate. Given the aggressive nature of malignant tumors, rapid decision-making during surgery is crucial. A newly developed surgical platform now enables critical decisions about tumor treatment to be made within minutes during operations.

Researchers at the Mayo Clinic (Rochester, MN, USA) employed mass spectrometry to detect key gene mutations, specifically isocitrate dehydrogenase (IDH) mutations, in brain cancer in real-time. Mass spectrometry, a sensitive technique for analyzing substances in tissue samples, including those altered in cancer, was pivotal in this study. Over 240 small tissue biopsies were collected from patients undergoing both asleep and awake brain surgeries for suspected glioma at Mayo Clinic between 2021 and 2023, with an additional 137 biopsies provided by an international collaborator. Neurosurgeons focused on the core of the tumor to identify the IDH mutation and also examined the surrounding tissues to determine if the cancer had spread.

During surgery, the tissue samples were placed on a glass slide, and the mass spectrometer enabled researchers to identify the presence of the IDH mutation within just two minutes, achieving 100% accuracy. This capability not only enhances the accuracy of real-time diagnoses but also allows surgeons to assess the patient’s prognosis more effectively and carry out tumor resections to improve outcomes. Going forward, this innovative platform could enable surgeons to utilize the critical window of opportunity in the operating room to customize treatments based on the molecular characteristics of the tumor, fostering a more personalized approach to medicine. The researchers are continuing their studies to identify additional molecular markers in tumors where the IDH mutation is absent and plan to extend their findings to other types of brain cancers.

“The ability to identify this mutation during brain surgery means that one day in the future we may be able to treat patients with this specific mutation locally before they leave the operating room,” said Alfredo Quiñones-Hinojosa, the study’s senior author. “Therefore, we will be able to bring the fight against cancer to the operating room, before chemotherapy and radiation treatments begin, and before the disease has progressed and invaded further.” The study was published in the journal PNAS on May 28, 2024.

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
All-in-one Molecular Diagnosis System
Panall 8000

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.